Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.6755
+0.0032 (0.48%)
At close: Oct 13, 2025, 4:00 PM EDT
0.6679
-0.0076 (-1.13%)
After-hours: Oct 13, 2025, 6:26 PM EDT
Sangamo Therapeutics Revenue
Sangamo Therapeutics had revenue of $18.31M in the quarter ending June 30, 2025, with 5,042.13% growth. This brings the company's revenue in the last twelve months to $81.71M, up 565.52% year-over-year. In the year 2024, Sangamo Therapeutics had annual revenue of $57.80M, down -67.20%.
Revenue (ttm)
$81.71M
Revenue Growth
+565.52%
P/S Ratio
1.84
Revenue / Employee
$446,481
Employees
183
Market Cap
203.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
| Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
| Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
| Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
| Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SGMO News
- 5 weeks ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call - GlobeNewsWire
- 3 months ago - Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire
- 5 months ago - Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - Business Wire
- 5 months ago - Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Business Wire